
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc continues to show robust growth, particularly with its cabozantinib (Cabo) franchise, which reported 20% year-over-year growth in the fourth quarter, amounting to $515.2 million in net product revenue for FY 2024. The company's strategic positioning in the metastatic renal cell carcinoma (RCC) market, along with a positive survey suggesting a significant demand for Cabo among oncologists treating advanced neuroendocrine tumors (NETs), indicates considerable upside potential for the treatment. Additionally, Exelixis is projected to achieve over $2 billion in revenue by 2025, bolstered by anticipated expansions in market penetration and the ongoing development of zanzalintinib.
Bears say
Exelixis Inc is facing significant risks that could adversely impact its stock outlook, primarily stemming from anticipated declines in market share for cabozantinib across various cancer settings due to potential failures in clinical programs, particularly regarding zanzalintinib. The company's revenue guidance appears conservative, not factoring in potential contributions from neuroendocrine tumors (NETs), which may signify future financial strain if the product fails to meet market expectations. Furthermore, the company's critical clinical data and ongoing developments indicate concerns over tolerability and competitive positioning that could further dilute its market presence, leading to negative long-term outlooks.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares